Meget tyder på, at disse immunomudulerende aktiviteter har betydning for antitumoreffekt f. eks. er tasonermin‘ s antitumoraktivitet mindre udtalt i immundefekte dyr.
Several lines of evidence suggest that these immunomodulatory activities are of relevance for the antitumour effects; e. g. the antitumour activities of tasonermin are much less pronounced in immunodeficient animals.